David Cunningham
Has grant
Professor Cancer Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Novel blood test to personalise Early Stage Colorectal Cancer treatment
Open Date: 2020-01-01
Close Date: 2027-12-31
Grant: Close
NIHR Royal Marsden Biomedical Research Centre
Open Date: 2012-04-01
Close Date: 2017-03-31
Grant: Close
CRUKE/11/020: CHEMO-T: CHOP verses GEM-P in the first line treatment Of T-cell Lymphoma
Open Date: 2011-10-01
Close Date: 2018-09-30
Grant: Close
CRUK/08/029: DLBCL: Feasibility study of R-CHOP plus Bevacizumab in patients with diffuse large B-cell Lymphoma
Open Date: 2008-06-01
Close Date: 2010-05-31
Grant: Close
CRUKE/07/049: REAL3: A randomized open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophagogastric cancer
Open Date: 2007-09-01
Close Date: 2012-08-31
Articles (29)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.
Year:
2026
Year:
2026
Objectives To evaluate the feasibility, safety, and technical performance of robot-assisted CT-guided cryoablation for pulmonary metastases. Materials and methods A single-centre IDEAL stage 2a prospective development study of 26 participants (median age 62 years, IQR 47–71; 14 men) who underwent 30 procedures targeting 37 lung metastases using a robotic navigation system. Median tumour diameter was 9.8 mm (IQR 5.1–12.8). All procedures were performed under general anaesthesia with high-frequency jet ventilation. Feasibility, safety, and technical performance (targeting accuracy, manipulations, radiation dose) were recorded. Results Robotic guidance was successfully completed without conversion in 35/37 tumours (95%). One major complication occurred (3%, CTCAE grade 3 pneumothorax requiring 4 days of drainage); all others were grade 1–2. Pneumothoraces were managed by observation ( n = 7) or prophylactic intraprocedural chest drain insertion ( n = 11). No bronchopleural fistulas were observed. Median hospital stay was 1 night (IQR 1–2). A total of 54 cryoprobes were used. Median Euclidean targeting error on first insertion was 6.1 mm (IQR 2.9–9.7) and lateral error 4.2 mm (IQR 2.2–6.5). The median number of manipulations per probe was 1 (IQR 0–2.5), with one-third requiring no adjustment. Once integrated into the workflow, the “chopstick” technique was frequently applied, supporting conformal ablation. Median total procedure time was 66.5 min (IQR 56.6–92.8). Twelve-month local tumour progression-free survival was 97%. Conclusion Robot-assisted CT-guided cryoablation of pulmonary metastases was feasible, safe, and accurate, achieving high targeting precision with minimal cryoprobe manipulation. These findings support evaluation in prospective comparative trials. Key Points Question Robotic-assisted CT-guided cryoablation of lung metastases is feasible and safe, achieving high targeting accuracy and minimal probe manipulation, even in anatomically challenging cases. Findings Robotic trajectory planning supported complex multiprobe configurations. Procedural refinements—including patient positioning, probe selection, and adoption of “chopstick” configurations—were introduced to address bleeding risk and optimise energy delivery. Clinical relevance Robot-assisted navigation is particularly advantageous in cryoablation, enabling minimal manipulations and accurate probe placement despite the often-necessary complex trajectories. Graphical Abstract
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (37)
John Bridgewater
UCL Cancer Institute
Chan Yoon Cheah
University of Western Australia
David Cairns
Professor of Clinical Trials Research
University of Leeds
Heike I Grabsch
Professor
University of Leeds
Jae-Ho Cheong
Professor
Yonsei University College of Medicine
David J. Pinato
Imperial College London
Henry Woodruff
Associate Professor
University of Maastricht
Andrew H. Briggs
London School of Hygiene & Tropical Medicine
Guglielmo Vetere
Assistant Professor - Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Yasmin Karimi
University of Michigan
Edward Johnston
Institute of Cancer Research
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
nicola valeri
Reader and Team Leader
Institute of Cancer Research
Alessio Cortellini
Imperial College London
Derek Magee
Associate Professor
University of Leeds
david tougeron
-
Caroline Kelly
Head of Biostatistics
-
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Michiel Henkens
Maastricht University Medical Centre
Ian Chau
Royal Marsden Hospital Sutton
Muti Abulafi
-
Michele Ghidini
Docenti di ruolo di IIa fascia
University of Insubria
Jayne Tierney
University College London
Luca Magnani
Docenti
University of Milan
Manuel Salto-Tellez
Lead
Institute of Cancer Research
Matteo Fassan
Docenti di ruolo di Ia fascia
University of Padova
Naureen Starling
Reader
Institute of Cancer Research
Leslie Samuel
University of Aberdeen
Jan Walewski
Professor of Medicine, Consultant in Medical Oncology
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Ruth Langley
University College London
Chiara Braconi
Chair in HepatoBiliary Oncology
University of Glasgow
Jamie Stokes
University of Oxford
Martin Hutchings
Professor
University of Copenhagen
Chiara Cremolini
University Hospital of Pisa
Hyunki Kim
Professor
Yonsei University College of Medicine
Lucinda Billingham
Professor of Biostatistics
University of Birmingham
Make your next move.
Prepare your application
Review drafts before you send them.